Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Benmelstobart in Advanced PPGL
NCT06429397Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- May 2025
- Primary completion
- May 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of benmelstobart in pheochromocytoma, Paraganglioma (PGL), sponsored by Sun Yat-sen University. Planned start May 2025; status: not yet recruiting.
02
Drugs
benmelstobart
03
Conditions
pheochromocytomaParaganglioma (PGL)
Beyond the preview
Go deeper on NCT06429397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06429397.